Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia

Background: Recently, one of the specific BH3-mimetics, Venetoclax has been approved by FDA providing new options for newly diagnosed AML patient especially who are unfitted to receive conventional chemotherapy. Though the clinical success of venetoclax has been achieved in clinical outcomes such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fang-jiao, Zeng, Chen-xing, Kuang, Wei, Cheng, Cong, Liu, Hong-cai, Yan, Xue-ying, Chen, Xiao-ping, Zhou, Gan, Cao, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518002/
https://www.ncbi.nlm.nih.gov/pubmed/34659562
http://dx.doi.org/10.7150/jca.60208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518002/
https://www.ncbi.nlm.nih.gov/pubmed/34659562
http://dx.doi.org/10.7150/jca.60208

Ejemplares similares